Allergan (NYSE:AGN) was downgraded by investment analysts at Vetr from a “buy” rating to a “hold” rating in a note issued to investors on Tuesday. They currently have a $171.99 price target on the stock. Vetr‘s price target would suggest a potential upside of 3.87% from the stock’s previous close.
Several other brokerages have also recently commented on AGN. Credit Suisse Group set a $214.00 price target on shares of Allergan and gave the stock a “buy” rating in a research report on Monday, January 22nd. Morgan Stanley reissued a “buy” rating on shares of Allergan in a research report on Wednesday, January 24th. Barclays raised shares of Allergan from an “equal weight” rating to an “overweight” rating and boosted their price target for the stock from $220.00 to $230.00 in a research report on Monday, January 29th. They noted that the move was a valuation call. ValuEngine cut shares of Allergan from a “buy” rating to a “hold” rating in a report on Friday, February 2nd. Finally, UBS set a $250.00 target price on shares of Allergan and gave the company a “buy” rating in a report on Wednesday, January 10th. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and fourteen have assigned a buy rating to the stock. Allergan currently has an average rating of “Hold” and a consensus target price of $220.91.
Shares of NYSE:AGN opened at $165.58 on Tuesday. The company has a current ratio of 1.16, a quick ratio of 1.06 and a debt-to-equity ratio of 0.38. Allergan has a one year low of $142.81 and a one year high of $256.80. The stock has a market cap of $58,113.34, a price-to-earnings ratio of 10.19, a price-to-earnings-growth ratio of 1.19 and a beta of 1.18.
In related news, insider Maria Teresa Hilado purchased 895 shares of the stock in a transaction on Thursday, March 15th. The shares were purchased at an average cost of $167.39 per share, with a total value of $149,814.05. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Brent L. Saunders purchased 3,300 shares of the stock in a transaction on Thursday, March 8th. The stock was bought at an average cost of $152.53 per share, for a total transaction of $503,349.00. The disclosure for this purchase can be found here. Over the last three months, insiders acquired 8,095 shares of company stock worth $1,258,081. Insiders own 0.36% of the company’s stock.
A number of institutional investors have recently added to or reduced their stakes in the business. KCM Investment Advisors LLC grew its position in shares of Allergan by 13.4% during the 4th quarter. KCM Investment Advisors LLC now owns 38,335 shares of the company’s stock worth $6,271,000 after purchasing an additional 4,539 shares in the last quarter. Colonial Trust Advisors acquired a new position in shares of Allergan during the 4th quarter worth approximately $470,000. Penbrook Management LLC acquired a new position in shares of Allergan during the 4th quarter worth approximately $978,000. Massmutual Trust Co. FSB ADV grew its position in shares of Allergan by 6.9% during the 4th quarter. Massmutual Trust Co. FSB ADV now owns 15,342 shares of the company’s stock worth $16,161,000 after purchasing an additional 994 shares in the last quarter. Finally, Pin Oak Investment Advisors Inc. acquired a new position in shares of Allergan during the 4th quarter worth approximately $1,787,000. 77.95% of the stock is currently owned by hedge funds and other institutional investors.
Allergan plc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes medical aesthetics, biosimilar, and over-the-counter pharmaceutical products worldwide. It operates through US Specialized Therapeutics, US General Medicine, and International segments. The company offers a portfolio of products that provide treatment for the central nervous system, gastroenterology, women's health and urology, ophthalmology, neurosciences, medical aesthetics, dermatology, plastic surgery, liver disease, inflammation, metabolic syndromes, and fibrosis, as well as Alzheimer's disease.
To view Vetr’s full report, visit Vetr’s official website.
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.